Advertisement

Tumor Biology

, Volume 36, Issue 10, pp 7399–7407 | Cite as

RETRACTED ARTICLE: Efficient inhibition of growth of metastatic cancer cells after resection of primary colorectal cancer by soluble Flt-1

  • Yong Zhang
  • Ao Li
  • Weizhen Peng
  • Jue Sun
  • Fangming Xu
  • Jianhua Xu
Research Article

Abstract

Removal of primary tumors often leads to increases in growth of metastatic tumor cells. Thus, development of an efficient treatment to inhibit the growth of metastatic tumor cells after resection of primary tumors appears to be critical for cancer therapy. Here, we reported that administration of a Chinese medicine Shiquandabutao (SQDBT) after removal of the primary cancer significantly inhibited the growth of metastatic cancer cells in mouse liver. Further analyses showed that the effect of SQDBT resulted from one of its main component, Siwutang (SWT), rather than from another main component, Sijunzitang (SJZT). Moreover, we found that the soluble Flt-1 from SWT neutralized the increased placental growth factor (PLGF) secreted by the metastatic cancer cells after primary cancer resection and subsequently inhibited the cancer neovascularization to suppress the metastatic cancer growth. Thus, our study reveals an essential role of SQDBT in inhibiting the growth of metastatic cancer after removal of primary cancer and further highlights PLGF as a potential target for metastatic cancer treatment.

Keywords

Colorectal cancer Vascular endothelial growth factor A (VEGF-A) Placental growth factor (PLGF) Soluble Flt-1 (sFlt-1) SQDBT SWT SJZT 

Notes

Acknowledgments

This work was financially supported by National Nature Science Foundation of China (no. 81273733).

Conflicts of interest

None

References

  1. 1.
    Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19:1821–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Aliperti LA, Predina JD, Vachani A, Singhal S. Local and systemic recurrence is the achilles heel of cancer surgery. Ann Surg Oncol. 2011;18:603–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Curcio LD, Chu DZ, Ahn C, Williams Jr WL, Paz IB, Riihimaki D, et al. Local recurrence in breast cancer: implications for systemic disease. Ann Surg Oncol. 1997;4:24–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Kosari K, Gomes M, Hunter D, Hess DJ, Greeno E, Sielaff TD. Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. J Gastrointest Surg. 2002;6:255–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Scott AD, Crane P, Staunton MD. Chondrosarcoma—local recurrence and systemic embolization. J R Soc Med. 1990;83:48–9.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Eichmann A, Simons M. Vegf signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24:188–93.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D, et al. Placenta growth factor-1 antagonizes vegf-induced angiogenesis and tumor growth by the formation of functionally inactive plgf-1/vegf heterodimers. Cancer Cell. 2002;1:99–108.CrossRefPubMedGoogle Scholar
  9. 9.
    Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-plgf inhibits growth of vegf(r)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of plgf in the intra- and intermolecular cross talk between the vegf receptors flt1 and flk1. Nat Med. 2003;9:936–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of vegf in mice. Diabetologia. 2014;57:991–1000.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res. 2000;60:2190–6.PubMedGoogle Scholar
  14. 14.
    Indraccolo S, Minuzzo S, Gola E, Habeler W, Carrozzino F, Noonan D, et al. Generation of expression plasmids for angiostatin, endostatin and timp-2 for cancer gene therapy. Int J Biol Markers. 1999;14:251–6.PubMedGoogle Scholar
  15. 15.
    Harris AL. Are angiostatin and endostatin cures for cancer? Lancet. 1998;351:1598–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Huang SM, Chien LY, Tai CJ, Chiou JF, Chen CS, Tai CJ. Effectiveness of 3-week intervention of shi quan da bu tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy. Integr Cancer Ther. 2013;12:136–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Mita Y, Dobashi K, Shimizu Y, Nakazawa T, Mori M. Surface expression of toll-like receptor 4 on thp-1 cells is modulated by bu-zhong-yi-qi-tang and shi-quan-da-bu-tang. Methods Find Exp Clin Pharmacol. 2002;24:67–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Wu Y, Zhang Y, Wu JA, Lowell T, Gu M, Yuan CS. Effects of erkang, a modified formulation of chinese folk medicine shi-quan-da-bu-tang, on mice. J Ethnopharmacol. 1998;61:153–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Tatsuta M, Iishi H, Baba M, Nakaizumi A, Uehara H. Inhibition by shi-quan-da-bu-tang (tj-48) of experimental hepatocarcinogenesis induced by n-nitrosomorpholine in Sprague–Dawley rats. Eur J Cancer. 1994;30A:74–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), sqt. A potent chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol. 1992;14:725–36.PubMedGoogle Scholar
  21. 21.
    Sakagami Y, Mizoguchi Y, Miyajima K, Kuboi H, Kobayashi K, Kioka K, et al. Antitumor activity of shi-quan-da-bu-tang and its effects on interferon-gamma and interleukin 2 production. Arerugi = [Allergy]. 1988;37:57–60.Google Scholar
  22. 22.
    Nishiuchi T, Okutani Y, Yamagishi Y, Fujita T, Imataki O, Ohnishi H, et al. Synergistic effect between juzen-taiho-to, a japanese traditional herbal medicine, and gemcitabine single-agent chemotherapy for advanced biliary tract cancer. J Altern Complement Med. 2013;19:593–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Sakamoto S, Kudo H, Kuwa K, Suzuki S, Kato T, Kawasaki T, et al. Anticancer effects of a chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. Am J Chinese Med. 1991;19:233–41.CrossRefGoogle Scholar
  24. 24.
    Saiki I. A kampo medicine “juzen-taiho-to”–prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull. 2000;23:677–88.CrossRefPubMedGoogle Scholar
  25. 25.
    Lian Z, Niwa K, Gao J, Tagami K, Hashimoto M, Yokoyama Y, et al. Shimotsu-to is the agent in juzen-taiho-to responsible for the prevention of endometrial carcinogenesis in mice. Cancer Lett. 2002;182:19–26.CrossRefPubMedGoogle Scholar
  26. 26.
    Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 1999;79:1392–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yong Zhang
    • 1
  • Ao Li
    • 1
  • Weizhen Peng
    • 1
  • Jue Sun
    • 1
  • Fangming Xu
    • 1
  • Jianhua Xu
    • 1
  1. 1.Department of Oncology, Putuo HospitalShanghai University of Traditional Chinese MedicineShanghaiChina

Personalised recommendations